Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis

<h4>Introduction</h4> Famotidine is a competitive histamine H2-receptor antagonist most commonly used for gastric acid suppression but thought to have potential efficacy in treating patients with Coronavirus disease 2019 (COVID-19). The aims of this systematic review and meta-analysis ar...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Leonard Chiu, Max Shen, Chun-Han Lo, Nicholas Chiu, Austin Chen, Hyun Joon Shin, Elizabeth Horn Prsic, Chin Hur, Ronald Chow, Benjamin Lebwohl
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/91d5b09a4c2648db86fca9cf1a96cd79
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:91d5b09a4c2648db86fca9cf1a96cd79
record_format	dspace
spelling	oai:doaj.org-article:91d5b09a4c2648db86fca9cf1a96cd792021-11-11T07:14:44ZEffect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis1932-6203https://doaj.org/article/91d5b09a4c2648db86fca9cf1a96cd792021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568101/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Introduction</h4> Famotidine is a competitive histamine H2-receptor antagonist most commonly used for gastric acid suppression but thought to have potential efficacy in treating patients with Coronavirus disease 2019 (COVID-19). The aims of this systematic review and meta-analysis are to summarize the current literature and report clinical outcomes on the use of famotidine for treatment of hospitalized patients with COVID-19. <h4>Methods</h4> Five databases were searched through February 12, 2021 to identify observational studies that reported on associations of famotidine use with outcomes in COVID-19. Meta-analysis was conducted for composite primary clinical outcome (e.g. rate of death, intubation, or intensive care unit admissions) and death separately, where either aggregate odds ratio (OR) or hazard ratio (HR) was calculated. <h4>Results</h4> Four studies, reporting on 46,435 total patients and 3,110 patients treated with famotidine, were included in this meta-analysis. There was no significant association between famotidine use and composite outcomes in patients with COVID-19: HR 0.63 (95% CI: 0.35, 1.16). Across the three studies that reported mortality separated from other endpoints, there was no association between famotidine use during hospitalization and risk of death—HR 0.67 (95% CI: 0.26, 1.73) and OR 0.79 (95% CI: 0.19, 3.34). Heterogeneity ranged from 83.69% to 88.07%. <h4>Conclusion</h4> Based on the existing observational studies, famotidine use is not associated with a reduced risk of mortality or combined outcome of mortality, intubation, and/or intensive care services in hospitalized individuals with COVID-19, though heterogeneity was high, and point estimates suggested a possible protective effect for the composite outcome that may not have been observed due to lack of power. Further randomized controlled trials (RCTs) may help determine the efficacy and safety of famotidine as a treatment for COVID-19 patients in various care settings of the disease.Leonard ChiuMax ShenChun-Han LoNicholas ChiuAustin ChenHyun Joon ShinElizabeth Horn PrsicChin HurRonald ChowBenjamin LebwohlPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Leonard Chiu Max Shen Chun-Han Lo Nicholas Chiu Austin Chen Hyun Joon Shin Elizabeth Horn Prsic Chin Hur Ronald Chow Benjamin Lebwohl Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis
description	<h4>Introduction</h4> Famotidine is a competitive histamine H2-receptor antagonist most commonly used for gastric acid suppression but thought to have potential efficacy in treating patients with Coronavirus disease 2019 (COVID-19). The aims of this systematic review and meta-analysis are to summarize the current literature and report clinical outcomes on the use of famotidine for treatment of hospitalized patients with COVID-19. <h4>Methods</h4> Five databases were searched through February 12, 2021 to identify observational studies that reported on associations of famotidine use with outcomes in COVID-19. Meta-analysis was conducted for composite primary clinical outcome (e.g. rate of death, intubation, or intensive care unit admissions) and death separately, where either aggregate odds ratio (OR) or hazard ratio (HR) was calculated. <h4>Results</h4> Four studies, reporting on 46,435 total patients and 3,110 patients treated with famotidine, were included in this meta-analysis. There was no significant association between famotidine use and composite outcomes in patients with COVID-19: HR 0.63 (95% CI: 0.35, 1.16). Across the three studies that reported mortality separated from other endpoints, there was no association between famotidine use during hospitalization and risk of death—HR 0.67 (95% CI: 0.26, 1.73) and OR 0.79 (95% CI: 0.19, 3.34). Heterogeneity ranged from 83.69% to 88.07%. <h4>Conclusion</h4> Based on the existing observational studies, famotidine use is not associated with a reduced risk of mortality or combined outcome of mortality, intubation, and/or intensive care services in hospitalized individuals with COVID-19, though heterogeneity was high, and point estimates suggested a possible protective effect for the composite outcome that may not have been observed due to lack of power. Further randomized controlled trials (RCTs) may help determine the efficacy and safety of famotidine as a treatment for COVID-19 patients in various care settings of the disease.
format	article
author	Leonard Chiu Max Shen Chun-Han Lo Nicholas Chiu Austin Chen Hyun Joon Shin Elizabeth Horn Prsic Chin Hur Ronald Chow Benjamin Lebwohl
author_facet	Leonard Chiu Max Shen Chun-Han Lo Nicholas Chiu Austin Chen Hyun Joon Shin Elizabeth Horn Prsic Chin Hur Ronald Chow Benjamin Lebwohl
author_sort	Leonard Chiu
title	Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis
title_short	Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis
title_full	Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis
title_fullStr	Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis
title_full_unstemmed	Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis
title_sort	effect of famotidine on hospitalized patients with covid-19: a systematic review and meta-analysis
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/91d5b09a4c2648db86fca9cf1a96cd79
work_keys_str_mv	AT leonardchiu effectoffamotidineonhospitalizedpatientswithcovid19asystematicreviewandmetaanalysis AT maxshen effectoffamotidineonhospitalizedpatientswithcovid19asystematicreviewandmetaanalysis AT chunhanlo effectoffamotidineonhospitalizedpatientswithcovid19asystematicreviewandmetaanalysis AT nicholaschiu effectoffamotidineonhospitalizedpatientswithcovid19asystematicreviewandmetaanalysis AT austinchen effectoffamotidineonhospitalizedpatientswithcovid19asystematicreviewandmetaanalysis AT hyunjoonshin effectoffamotidineonhospitalizedpatientswithcovid19asystematicreviewandmetaanalysis AT elizabethhornprsic effectoffamotidineonhospitalizedpatientswithcovid19asystematicreviewandmetaanalysis AT chinhur effectoffamotidineonhospitalizedpatientswithcovid19asystematicreviewandmetaanalysis AT ronaldchow effectoffamotidineonhospitalizedpatientswithcovid19asystematicreviewandmetaanalysis AT benjaminlebwohl effectoffamotidineonhospitalizedpatientswithcovid19asystematicreviewandmetaanalysis
_version_	1718439419949613056

Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis

Ejemplares similares